Order Article Reprints

Karci E, Bilici A, Bayram B, Celayir M, Ozyurt N, Uluc BO, Eken A, Basaran G, Demirci U, Kemal Y, et al. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. Cancers. 2024; 16(19):3389. https://doi.org/10.3390/cancers16193389

Karci, Ebru, Ahmet Bilici, Buket Bayram, Melisa Celayir, Neslihan Ozyurt, Başak Oyan Uluc, Aynur Eken, Gul Basaran, Umut Demirci, Yasemin Kemal, and et al. 2024. "Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study" Cancers 16, no. 19: 3389. https://doi.org/10.3390/cancers16193389

Karci, E., Bilici, A., Bayram, B., Celayir, M., Ozyurt, N., Uluc, B. O., Eken, A., Basaran, G., Demirci, U., Kemal, Y., Oruncu, M. B., Olmez, O. F., Selcukbiricik, F., Korkmaz, T., Erturk, I., Bilgetekin, I., Celik, S., Turkel, A., Alkan, A., ... Yildiz, O. (2024). Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study. Cancers, 16(19), 3389. https://doi.org/10.3390/cancers16193389